Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENT: Carfilzomib, Lenalidomide, Daratumumab, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
NCT03289299Phase 2Active, not recruiting
- Sponsor
- International Myeloma Foundation
- Start
- May 2018
- Primary completion
- Sep 2023
- Modality
- Reversible Covalent Inhibitors, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib, lenalidomide, daratumumab and dexamethasone in smoldering multiple myeloma (SMM), sponsored by International Myeloma Foundation. Primary endpoint: Stringent Complete Response Rate. Started May 2018; status: active, not recruiting.
02
Drugs
carfilzomiblenalidomidedaratumumabdexamethasone
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT03289299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03289299.